Literature DB >> 20573523

Improvement in bedtime plasma glucose level serves as a predictor of long-term blood glucose control in patients with Type 2 diabetes: a study with monotherapy of 50/50 premixed insulin analogue three times daily injection.

Masami Tanaka1, Hitoshi Ishii.   

Abstract

AIM: To examine which timing of blood glucose level is more important to achieve adequate blood glucose control with insulin lispro mixture-50 (Mix 50) three times daily (TID) monotherapy.
METHODS: The study enrolled 35 Type 2 diabetic patients. Blood glucose levels before each meal and at bedtime were measured 2 weeks after the start of the study and were analyzed in relation to improvement in hemoglobin A1c (HbA1c) at 6-8 weeks and 6 months.
RESULTS: HbA1c improved significantly (10.1±1.6 % at baseline, 7.8±1.1 % at 6-8 weeks and 6.8±1.1 % at 6 months). Only the blood glucose level measured at bedtime correlated with improvement in HbA1c at 6-8 weeks. For the insulin-naïve patients, only bedtime plasma glucose level also had a significant correlation with improvement in HbA1c at 6 months.
CONCLUSIONS: Bedtime plasma glucose level can serve as a predictor of the outcome of long-term blood glucose control during Mix 50 TID monotherapy and that bedtime plasma glucose level needs to be reduced sufficiently to achieve adequate blood glucose control.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20573523     DOI: 10.1016/j.jdiacomp.2010.05.001

Source DB:  PubMed          Journal:  J Diabetes Complications        ISSN: 1056-8727            Impact factor:   2.852


  2 in total

1.  Intersubject variability of blood analysis reference values: assessment of age and locality influence by means of a linear discriminant analysis model.

Authors:  João C M Barreira; Roberto Costa; M Graça Pombo; Isabel C F R Ferreira
Journal:  J Clin Lab Anal       Date:  2013-02-20       Impact factor: 2.352

Review 2.  Use of 50/50 Premixed Insulin Analogs in Type 2 Diabetes: Systematic Review and Clinical Recommendations.

Authors:  Gary Deed; Gary Kilov; Trisha Dunning; Richard Cutfield; Jane Overland; Ted Wu
Journal:  Diabetes Ther       Date:  2017-11-07       Impact factor: 2.945

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.